Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $94000.0.

  • Verrica Pharmaceuticals' Gains from Investment Securities fell 5668.2% to $94000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $651000.0, marking a year-over-year increase of 1361.26%. This contributed to the annual value of $924000.0 for FY2024, which is 391739.13% up from last year.
  • Verrica Pharmaceuticals' Gains from Investment Securities amounted to $94000.0 in Q3 2025, which was down 5668.2% from $85000.0 recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Gains from Investment Securities ranged from a high of $374000.0 in Q4 2024 and a low of $1000.0 during Q2 2021
  • Moreover, its 5-year median value for Gains from Investment Securities was $54000.0 (2023), whereas its average is $88071.4.
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Gains from Investment Securities surged by 152608.7% in 2024, and later crashed by 5668.2% in 2025.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' Gains from Investment Securities stood at $2000.0 in 2021, then changed by 0.0% to $2000.0 in 2022, then skyrocketed by 1050.0% to $23000.0 in 2023, then skyrocketed by 1526.09% to $374000.0 in 2024, then plummeted by 74.87% to $94000.0 in 2025.
  • Its last three reported values are $94000.0 in Q3 2025, $85000.0 for Q2 2025, and $98000.0 during Q1 2025.